| 证券代码 | KIN.O |
| 证券名称 | Kindred Biosciences Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2013-12-12 |
| 首发价格(元) | 7 USD |
| 首发数量(股) | 7500000 |
| 首发募资额(元) | 52,500,000.00 USD |
| 首发主承销商 | BMO Capital Markets Corp,Guggenheim Securities, LLC |
| 货币单位 | USD |
| 公司名称 | Kindred Biosciences, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 1555 Bayshore Highway, Suite 200, Burlingame, California, USA |
| 成立日期 | 2012-09-25 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.kindredbio.com |
| 电话 | +1 (650) 701-7901 |
| 传真 | - |
| 公司简介 | Kindred Biosciences, Inc. is a pre-commercialization biopharmaceutical company focused on saving and improving the lives of pets. Their mission is to bring to their pets the same kinds of safe and effective medicines that their human family members enjoy. Their core strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for pets, primarily dogs, cats and horses. They believe this approach will lead to shorter development times and higher approval rates than pursuing new, non-validated compounds and targets.Their current portfolio includes over 20 product candidates in development consisting of both small molecule pharmaceuticals and biologics. |